Ruxolitinib

Where the papers sit

14 papers from the last 6 months study ruxolitinib directly · updated from PubMed 12 Oct 2026

• Broad JAK Inhibitor Use

  Ruxolitinib is being used across myelofibrosis, immune-mediated disease, and inflammatory skin disorders rather than within one disease pathway. Selinexor combination therapy is being tested in JAK inhibitor-naïve myelofibrosis, while topical JAK inhibition targets facial vitiligo and atopic dermatitis. Emapalumab combinations address pediatric HLH, and ruxolitinib is reported for corticosteroid-refractory hypereosinophilic syndrome. Pharmacokinetics and exposure-toxicity relationships remain a recurring concern across hematologic and immune indications.

  7 papers · 50%

• Myeloproliferative Neoplasm Care

  Ruxolitinib remains central to real-world management of polycythemia vera and myelofibrosis, with outcomes tracked beyond registration trials. Hydroxycarbamide comparisons, long-term prognostic modeling, and high-dose exposure studies focus on response, safety, and treatment durability. After ruxolitinib failure, momelotinib is emerging as a practical option, with predictors of benefit under study. Hemorrhagic and thrombotic events remain important endpoints in selecting dose and sequencing therapy.

  4 papers · 28.6%

• Graft-Versus-Host Disease

  JAK inhibition is extending from treatment of established GVHD to prevention after haploidentical transplantation and local control of skin disease. Low-dose ruxolitinib is being tested prophylactically, while topical treatment targets chronic cutaneous GVHD with intra-patient randomized comparisons. Long-term follow-up addresses durability across acute and chronic GVHD and helps define delayed toxicity. The key open question is how preventive, systemic, and topical strategies should be sequenced.

  3 papers · 21.4%